H1N1 virus-like particle vaccine - Novavax / Cadila

Drug Profile

H1N1 virus-like particle vaccine - Novavax / Cadila

Alternative Names: Cadiflu; H1N1 virus-like particle (VLP) vaccine - Novavax / Cadila; Influenza VLP vaccines - Novavax / Cadila; Monovalent influenza A (H1N1 2009) virus like particle (VLP) vaccine - Cadila / Novavax; Pandemic influenza A H1N1 VLP vaccine - Novavax / Cadila; Swine flu vaccine - Novavax / Cadila; Unadjuvanted 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine - Novavax / Cadila

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Novavax
  • Developer Cadila Pharmaceuticals; CPL Biologicals; Novavax
  • Class Influenza A virus H1N1 vaccines; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 31 Dec 2012 CPL Biologicals initiates a phase I trial of its Influenza-A virus H1N1 subtype vaccine in India
  • 04 Aug 2011 Final immunogenicity data from a phase II trial in Influenza-A virus H1N1 subtype (Prevention) released by Novavax
  • 01 Mar 2011 Novavax receives a contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of Influenza virus-like particle vaccines in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top